At a Glance
- Companies: Scenic Biotech; Ono Pharmaceutical Co., Ltd.
- Location: Amsterdam, Netherlands (Scenic); Tokyo, Japan (Ono)
- Deal value: Undisclosed financial terms
- Focus area: Novel therapeutic targets discovered via Scenic’s Cell-Seq genetic modifier platform for undisclosed indications
- Next steps: Ono to develop and commercialise selected targets; Scenic’s fourth major Cell-Seq partnership
What happened?
Scenic Biotech has entered a licence and research agreement with Ono Pharmaceutical Co., Ltd., granting Ono rights to novel therapeutic targets identified using Scenic’s proprietary Cell-Seq platform for undisclosed indications. The deal marks Scenic’s fourth major partnership for Cell-Seq, following collaborations with Genentech, Bristol Myers Squibb and Alnylam, and allows Ono to advance selected targets through its development and commercialisation pipeline.
Why does it matter?
Cell-Seq is a genome‑wide, unbiased platform that identifies genetic modifiers—genes that influence disease severity or progression independently of the primary genetic cause—offering a novel approach to discovering actionable targets for both rare and common diseases. Ono, with its focus on oncology, immunology, neurology and unmet needs, gains access to this technology to uncover differentiated biology, potentially accelerating its pipeline in high‑value areas where traditional target identification falls short.
Who’s behind it?
Scenic Biotech is a Netherlands‑based pioneer in modifier therapies, using Cell-Seq to map cellular pathways and develop first‑in‑class small‑molecule treatments for serious diseases. Ono Pharmaceutical is a Japanese global player committed to addressing unmet medical needs through internal R&D and strategic biotech partnerships, including recent deals in GPCR antibodies, CRISPRomics and AI platforms.
How was it achieved?
Under the agreement, Scenic applies Cell-Seq to Ono‑selected biology, generating validated target hypotheses that Ono can license for exclusive worldwide development and commercialisation. Financial terms are undisclosed, but the structure aligns with Scenic’s prior partnerships, likely including upfront payments, research funding and downstream milestones tied to clinical and commercial progress.
What’s next?
Ono will evaluate and prioritise Cell-Seq outputs for preclinical advancement, potentially feeding into its oncology, immunology or neurology franchises. For Scenic, this validates Cell-Seq’s broad applicability and supports its proprietary pipeline of modifier therapies, with further partnerships likely as the platform demonstrates target quality across modalities.
What are people saying?
Scenic CSO Roland W. Bürli described the Ono deal as a “significant endorsement” of Cell-Seq’s ability to reveal new disease mechanisms and innovative targets for serious conditions. The partnership reflects Ono’s strategy of collaborating with academia and biotechs to expedite discovery and expand its global pipeline.